NSE: BETA · ISIN INE351Y01019
Beta Drugs Limited stock analysis
Beta Drugs Limited ranks #1143 in the TickerSutra evidence-ranked universe with a score of 56/100 and 93% data confidence. The latest captured fundamentals show ROCE of 19.2%, quarterly sales growth of 25.3% and quarterly profit growth of 35.0%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- 19.3% three-year sales CAGR
- Institutional ownership is rising
- No promoter shares are reported as pledged
Risks and constraints
- Debt/equity is above 0.5×
- CFO/EBITDA is below 0.6×
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹184cr | ₹43cr | ₹25cr | 23.0% |
| 2023 | ₹227cr | ₹53cr | ₹31cr | 23.0% |
| 2024 | ₹296cr | ₹60cr | ₹36cr | 20.0% |
| 2025 | ₹362cr | ₹75cr | ₹42cr | 21.0% |
| 2026 | ₹385cr | ₹76cr | ₹41cr | 20.0% |
| TTM | ₹410cr | ₹83cr | ₹46cr | 20.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Beta Drugs Limited has informed the Exchange about Azerbaijan Oncology Market Regulatory & Commercialisation update
RoutineAnalysts/Institutional Investor Meet/Con. Call UpdatesNSE · 10 Sept 2026Beta Drugs Limited has informed the Exchange about Schedule of meet
MANAGEMENT COMMENTARY
Signals from filed documents
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…